Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia

BACKGROUND: Thrombopoietin-receptor agonists eltrombopag (EPAG) and romiplostim (ROMI) are treatment options for adults with chronic immune thrombocytopenia (cITP) who have had an insufficient response to corticosteroids or immunoglobulins. METHODS: A cost-consequence model was developed to evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales: Tremblay, Gabriel, Dolph, Mike, Bhor, Menaka, Said, Qayyim, Elliott, Brian, Briggs, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219311/
https://www.ncbi.nlm.nih.gov/pubmed/30464563
http://dx.doi.org/10.2147/CEOR.S177324

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219311/
https://www.ncbi.nlm.nih.gov/pubmed/30464563
http://dx.doi.org/10.2147/CEOR.S177324

Ejemplares similares